ABBN:SIX

ABB Ltd.

Data as of 2026-03-09 - not real-time

$85.09

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

ABB Ltd (ABBN) is trading at $85.09, comfortably above its 20‑day SMA of $89.41 and the 50‑day SMA of $82.84, indicating a short‑term pull‑back within a broader bullish trend (200‑day SMA $71.09). Technical signals are mixed: the MACD histogram is negative and the MACD line sits below the signal line, flagging bearish momentum, while the RSI at 44.7 suggests the stock is not yet oversold. Volatility is elevated at roughly 40% over the past 30 days, but a beta of 0.73 points to lower systematic risk than the market. On the fundamentals side, revenue grew 5.4% year‑over‑year, margins remain solid (gross 41%, operating 16.8%), and ROE stands at an impressive 29%, supported by a healthy free cash flow generation of $1.30 bn. However, the valuation is stretched – a trailing P/E of 34 versus an industry average of 29, a price‑to‑book of 9.6, and a DCF‑derived fair value of just $10.97 imply the stock is significantly overvalued, with a downside potential of about 7.5% from current levels. The dividend yield of 1.44% and a payout ratio of 41% are sustainable, and the recent share buyback of 231,530 shares adds modest support. Overall, the blend of strong earnings fundamentals and a high valuation, combined with rising volume and a recent buyback, suggests a cautious stance pending price correction.

Trading Recommendations

Short Term

< 1 year
hold
Conviction: 6/10

Key Factors

  • Price near recent support at $81.23
  • Bearish MACD histogram despite overall bullish trend
  • Increasing volume indicating continued market interest

Medium Term

1–3 years
hold
Conviction: 5/10

Key Factors

  • Solid revenue and earnings growth with strong ROE
  • High valuation metrics relative to peers
  • Sustainable dividend and recent share buyback

Long Term

> 3 years
hold
Conviction: 5/10

Key Factors

  • Long‑term exposure to electrification, motion and automation markets
  • Overvaluation risk highlighted by DCF fair value
  • Stable cash generation and moderate debt levels

Key Metrics & Analysis

Financial Health

Revenue Growth5.40%
Profit Margin14.25%
P/E Ratio34.2
ROE29.39%
ROA8.67%
Debt/Equity55.48
P/B Ratio9.6
Op. Cash Flow$5.5B
Free Cash Flow$1.3B
Industry P/E29.5

Technical Analysis

TrendBullish
RSI44.7
Support$81.23
Resistance$93.40
MA 20$89.41
MA 50$82.84
MA 200$71.09
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89

Valuation

Fair Value$10.97
Target Price$78.75
Upside/Downside-7.45%
GradeOvervalued
TypeGrowth
Dividend Yield1.44%

Risk Assessment

Beta0.73
Volatility39.55%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.